These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

551 related items for PubMed ID: 27756537

  • 1. Differences in cleavage of globotriaosylceramide and its derivatives accumulated in organs of young Fabry mice following enzyme replacement therapy.
    Kodama T, Tsukimura T, Kawashima I, Sato A, Sakuraba H, Togawa T.
    Mol Genet Metab; 2017; 120(1-2):116-120. PubMed ID: 27756537
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effects of switching from agalsidase-α to agalsidase-β on biomarkers, renal and cardiac parameters, and disease severity in fabry disease forming neutralizing antidrug antibodies: a case report.
    Shima H, Tsukimura T, Shiga T, Togawa T, Sakuraba H, Doi T, Ikeda Y, Okamoto T, Yoshikawa Y, Kimura T, Iwase T, Inoue T, Tashiro M, Okada K, Minakuchi J.
    CEN Case Rep; 2024 Aug; 13(4):290-296. PubMed ID: 38135868
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
    Tsuboi K, Yamamoto H.
    BMC Pharmacol Toxicol; 2017 Jun 07; 18(1):43. PubMed ID: 28592315
    [Abstract] [Full Text] [Related]

  • 5. Pathogenesis and Molecular Mechanisms of Anderson-Fabry Disease and Possible New Molecular Addressed Therapeutic Strategies.
    Tuttolomondo A, Simonetta I, Riolo R, Todaro F, Di Chiara T, Miceli S, Pinto A.
    Int J Mol Sci; 2021 Sep 18; 22(18):. PubMed ID: 34576250
    [Abstract] [Full Text] [Related]

  • 6. Reduced glucosylceramide in the mouse model of Fabry disease: correction by successful enzyme replacement therapy.
    Quinta R, Rodrigues D, Assunção M, Macedo MF, Azevedo O, Cunha D, Oliveira P, Sá Miranda MC.
    Gene; 2014 Feb 15; 536(1):97-104. PubMed ID: 24334116
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Plasma globotriaosylsphingosine as a biomarker of Fabry disease.
    Togawa T, Kodama T, Suzuki T, Sugawara K, Tsukimura T, Ohashi T, Ishige N, Suzuki K, Kitagawa T, Sakuraba H.
    Mol Genet Metab; 2010 Jul 15; 100(3):257-61. PubMed ID: 20409739
    [Abstract] [Full Text] [Related]

  • 9. Diurnal Variation of Urinary Fabry Disease Biomarkers during Enzyme Replacement Therapy Cycles.
    Boutin M, Lavoie P, Menkovic I, Toupin A, Abaoui M, Elidrissi-Elawad M, Arthus MF, Fortier C, Ménard C, Maranda B, Bichet DG, Auray-Blais C.
    Int J Mol Sci; 2020 Aug 25; 21(17):. PubMed ID: 32854306
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Mechanisms of Neutralizing Anti-drug Antibody Formation and Clinical Relevance on Therapeutic Efficacy of Enzyme Replacement Therapies in Fabry Disease.
    Lenders M, Brand E.
    Drugs; 2021 Nov 25; 81(17):1969-1981. PubMed ID: 34748189
    [Abstract] [Full Text] [Related]

  • 14. Use of a modified alpha-N-acetylgalactosaminidase in the development of enzyme replacement therapy for Fabry disease.
    Tajima Y, Kawashima I, Tsukimura T, Sugawara K, Kuroda M, Suzuki T, Togawa T, Chiba Y, Jigami Y, Ohno K, Fukushige T, Kanekura T, Itoh K, Ohashi T, Sakuraba H.
    Am J Hum Genet; 2009 Nov 25; 85(5):569-80. PubMed ID: 19853240
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cell Transplantation Combined with Recombinant Collagen Peptides for the Treatment of Fabry Disease.
    Kami D, Yamanami M, Tsukimura T, Maeda H, Togawa T, Sakuraba H, Gojo S.
    Cell Transplant; 2020 Nov 25; 29():963689720976362. PubMed ID: 33300391
    [Abstract] [Full Text] [Related]

  • 19. Treatment of neutral glycosphingolipid lysosomal storage diseases via inhibition of the ABC drug transporter, MDR1. Cyclosporin A can lower serum and liver globotriaosyl ceramide levels in the Fabry mouse model.
    Mattocks M, Bagovich M, De Rosa M, Bond S, Binnington B, Rasaiah VI, Medin J, Lingwood C.
    FEBS J; 2006 May 25; 273(9):2064-75. PubMed ID: 16724420
    [Abstract] [Full Text] [Related]

  • 20. Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome.
    Rombach SM, Aerts JM, Poorthuis BJ, Groener JE, Donker-Koopman W, Hendriks E, Mirzaian M, Kuiper S, Wijburg FA, Hollak CE, Linthorst GE.
    PLoS One; 2012 May 25; 7(10):e47805. PubMed ID: 23094092
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.